author-photo

Marie-Anne Damiette Smit

Amgen

9

Papers

90

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

P15.01 AMG 757, a Half-Life Extended Bispecific T-Cell Engager (HLE BiTE® Immune Therapy) Targeting DLL3, for the Treatment of Small Cell Lung Cancer

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (11)